About
Adaptive Immune Cell Therapies
Areas of Focus
Categories
Stem Cell & Cellular TherapyVirginia, DC, DE & Maryland
Clinical Trials (5)
View allTotal Trials
5
As Lead Sponsor
2
As Collaborator
3
Total Enrollment
673
By Phase
PHASE1: 3PHASE3: 1PHASE2: 1
By Status
RECRUITING: 3ACTIVE_NOT_RECRUITING: 2
Clinical Trials Pipeline5 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
Today
Hover over trial bars to see details
Recent Trials
NCT06626919Lead Sponsor
A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases
PHASE1Recruiting
30 participants
Started: Apr 30, 2025 · Completed: Apr 30, 2028
NCT06413498Collaborator
A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
PHASE3Recruiting
450 participants
Started: Aug 23, 2024 · Completed: Jul 31, 2031
NCT05457010Lead Sponsor
Phase I Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory AML or High-risk MDS
PHASE1Recruiting
24 participants
Started: Nov 28, 2022 · Completed: Nov 17, 2025
NCT05396885Collaborator
Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1)
PHASE2Active, not recruiting
129 participants
Started: Aug 9, 2022 · Completed: Dec 31, 2026
NCT04155749Collaborator
Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple Myeloma
PHASE1Active, not recruiting
40 participants
Started: Dec 23, 2019 · Completed: Jun 30, 2026
Locations (1)
Headquarters
Rockville, MD, United States
Map
Loading map...